Germany, May 13 -- Germany based AstraZeneca GmbH has secured contract from DAK-Gesundheit for Pharmaceutical Products - Completion of a non -exclusive discount agreement according to Section 130a (8) SGB V for the active ingredient Benralizumab, ATC R03DX10 for the time 01062023 - 31052025. The value of the contract is not disclosed.
Published by HT Digital Content Services with permission from Pivotal Sources....